Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $7.4 billion.

  • United Therapeutics' Liabilities and Shareholders Equity rose 320.09% to $7.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $30.4 billion, marking a year-over-year increase of 1039.13%. This contributed to the annual value of $7.4 billion for FY2024, which is 274.87% up from last year.
  • As of Q3 2025, United Therapeutics' Liabilities and Shareholders Equity stood at $7.4 billion, which was up 320.09% from $7.9 billion recorded in Q2 2025.
  • United Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $7.9 billion during Q2 2025, with a 5-year trough of $4.6 billion in Q1 2021.
  • In the last 5 years, United Therapeutics' Liabilities and Shareholders Equity had a median value of $6.5 billion in 2024 and averaged $6.3 billion.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 2148.19% in 2023, then skyrocketed by 62.71% in 2024.
  • United Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $5.2 billion in 2021, then rose by 16.94% to $6.0 billion in 2022, then increased by 18.57% to $7.2 billion in 2023, then increased by 2.75% to $7.4 billion in 2024, then decreased by 0.18% to $7.4 billion in 2025.
  • Its Liabilities and Shareholders Equity was $7.4 billion in Q3 2025, compared to $7.9 billion in Q2 2025 and $7.7 billion in Q1 2025.